美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.36

+0.10590.31%

盤後：34.360.0041+0.01%16:15 EDT

成交量：1.97萬

成交額：67.69萬

市值：9,550.94萬

市盈率：- -

高：34.62

開：34.39

低：34.20

收：34.25

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：0.95

換手率：0.71%

股息：0.26

股息率：0.75%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

興齊眼藥：SQ-25012注射液獲臨床試驗批准通知書

港股異動 | 海西新藥(02637)升逾3% 近期已遞交HX9428的DME IIa期新藥臨床試驗申請

市場持續縮量或臨近變盤，網絡安全概念與創新藥成結構性亮點

智通港股早知道 | 國產創新藥WCLC數據密集兑現投行看好中國CRO/CDMO復甦明確

對外授權交易總額約1100億美元！2026年上半年創新藥「出海」觀察：多款獲批生物類似藥寄望海外收入超越國內

每日经济新闻

創新藥板塊迎來近一個月最大漲幅，這些國產創新藥在「2026世界肺癌大會」讀出亮眼數據

每日经济新闻

CRO板塊強勢走高！多家CRO上市公司解密業務近況

微博财经-财道工作室

我國創新藥出海再提速今年對外授權突破1200億美元

智通港股解盤 | 美國放緩AI另有玄機 WCLC大會再度催化創新藥

縮量震盪下，創新藥逆市爆發，中證銀行指數上探年內新高！光模塊回調，高「光」ETF獲資金逢低關注

博安生物：BA1203獲准開展臨床試驗

南方财经网

ETF日報：短期看在A股整體市場動能偏弱、熱點輪動加快的環境下，前期調整的創新藥、CXO板塊擁有一定性價比

康哲藥業(00867)：創新藥高選擇性TYK2抑制劑CMS-D001 獲得系統性紅斑狼瘡適應症藥物臨床試驗批准通知書

康哲藥業：9月14日CMS-D001獲SLE臨床試驗批准

恒瑞創新藥凝血因子XI單抗SHR-2004注射液用於擇期膝關節置換手術後成年患者靜脈血栓預防的上市申請獲受理

白雲山：超10個創新藥管線引進項目已完成立項

ETF日報(09.14)丨WCLC臨床數據密集兑現，創新藥板塊震盪回升算力需求預期遭重估

阿斯利康(AZN.US)乳腺癌藥物Etcamah三期臨床試驗受挫或致數十億美元銷售額蒙陰

阿斯利康(AZN.US)乳腺癌藥物Etcamah三期臨床試驗受挫或致數十億美元銷售額蒙陰

ETF異動 | 華夏恒生生科(03069)升逾4% WCLC臨床數據催化密集機構看好創新藥投資機會

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/IBBQ/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.3559,"timestamp":1789588800000,"preClose":34.25,"halted":0,"volume":19671,"hourTrading":{"tag":"盘后","latestPrice":34.36,"preClose":34.3559,"latestTime":"16:15 EDT","volume":44,"amount":1508.319428,"timestamp":1789589700352,"change":0.0041,"changeRate":0.000119,"amplitude":0.010187},"delay":0,"changeRate":0.003091970802919659,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"盤後交易","change":0.1059,"latestTime":"09-16 18:35:57 EDT","open":34.39,"high":34.62,"low":34.1992,"amount":676854,"amplitude":0.012286,"askPrice":34.72,"askSize":8201,"bidPrice":34.35,"bidSize":1,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":34.25,"sharesOutstanding":2520001,"nav":34.76286,"aum":96640785.56286,"dividendRate":0.007478,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":34.28,"preClose":34.25,"latestTime":"09:29 EDT","volume":69,"amount":2360.8497660000003,"timestamp":1789565397037,"change":0.03,"changeRate":0.000876,"amplitude":0.008175},"postHourTrading":{"tag":"盘后","latestPrice":34.36,"preClose":34.3559,"latestTime":"16:15 EDT","volume":44,"amount":1508.319428,"timestamp":1789589700352,"change":0.0041,"changeRate":0.000119,"amplitude":0.010187},"volumeRatio":0.94973,"impliedVol":0.1125,"impliedVolPercentile":0.4741},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.94973,"shares":2780001,"dividePrice":0.2569,"high":34.62,"amplitude":0.012286,"preClose":34.25,"low":34.1992,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.3559,"committee":-0.999756,"eps":0,"divideRate":0.007478,"volume":19671,"delay":0,"ttmEps":0,"open":34.39,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":34.9277,"twentyDayClose":34.6197,"sixtyDayClose":30.4995},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667617589","title":"興齊眼藥：SQ-25012注射液獲臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2667617589","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667617589?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 15:51","pubTimestamp":1789458674,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","BMED","PSYK","IBBJ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667148376","title":"港股異動 | 海西新藥(02637)升逾3% 近期已遞交HX9428的DME IIa期新藥臨床試驗申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2667148376","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667148376?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 14:48","pubTimestamp":1789454932,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海西新药涨超3%，截至发稿，涨2.89%，报195.5港元，成交额618.26万港元。消息面上，海西新药发布公告，本公司自主研发的创新药项目HXP056的候选药物分子HX9428，已于2026年8月31日正式向中国国家药品监督管理局药品审评中心递交新适应症糖尿病性黄斑水肿的IIa期新药临床试验申请。公司表示，将继续全力推进HX9428在中美两地多项临床研究的进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496128.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","KCAI","02637","BK1191","BK4588","IBBJ","PSYK","IBBQ","MDTX","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667697929","title":"市場持續縮量或臨近變盤，網絡安全概念與創新藥成結構性亮點","url":"https://stock-news.laohu8.com/highlight/detail?id=2667697929","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667697929?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 09:28","pubTimestamp":1789435718,"startTime":"0","endTime":"0","summary":"　　昨日市场延续弱势震荡，三大指数全线收跌，量能进一步萎缩，仅剩1.63万亿，通常而言持续缩量震荡后市场面临着变盘节点，静待后续的方向选择。　　网络安全概念成为昨日市场最大亮点，逆势走出独立走强行情。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/zldongxiang/20260915/32369725.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["HAKY","SKYY","XT","DRES","CRWC","159992","BPAY","EIS","BCTK","IBBQ","SPAM","UCYB","FDIF","FDFF","BK1161","PSWD","LNGR","WCBR","LOUP","NBDS","06978","PSCT","KOMP","INVN","CIBR","IHAK","BK4585","NSI","TEKX","GSFP","FITE","BK4588","CRTC","CRWL","FWD","TEK","MEDX","USMD","BUG","MVPS","TEKY","BK1574","ANEW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667691412","title":"智通港股早知道 | 國產創新藥WCLC數據密集兑現 投行看好中國CRO/CDMO復甦明確","url":"https://stock-news.laohu8.com/highlight/detail?id=2667691412","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667691412?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 07:29","pubTimestamp":1789428595,"startTime":"0","endTime":"0","summary":"WCLC临床数据密集兑现，国内外投行相继看好中国CRO/CDMO复苏明确9月12日至15日，2026年世界肺癌大会在韩国首尔举行，多项国产创新药临床数据集中亮相，中国新药入选口头报告19项、小型口头报告45项，双双刷新历史纪录，肺癌领域ADC与双抗数据成为焦点。经初步测算，本次交易完成后，一汽股份将成为公司第二大和具有战略影响力的股东;本次交易预计构成重大资产重组及关联交易，不构成公司实际控制人变更，不构成重组上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495955.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1147","IE00B5MMRT66.SGD","BK1144","BK1183","LU1226287875.USD","LU1951186391.HKD","IE00BZ08YT58.USD","LNGR","BK1191","06978","LU0326950275.SGD","BK1119","06871","HK0000165453.HKD","IBBQ","MEDX","VXUS","LU0315179316.USD","LU0501845795.SGD","LU1152091754.HKD","BK1539","BK4139","LU1226288170.HKD","LU1813983027.USD","KURE","02889","IE0008368742.USD","CDMO","IE00B543WZ88.USD","LU1960683339.HKD","159992","LU1993786604.SGD","BK1574","SG9999004220.SGD","01911","LU1328277881.USD","BK4585","KCAI","LU0314109678.HKD","LU1008478684.HKD","LU0140636845.USD","LU1226287792.SGD","01093","BK4588","IE0008369823.USD","LU2039709279.SGD","BK1521","02238","BK1161","LU1226287529.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667660668","title":"對外授權交易總額約1100億美元！2026年上半年創新藥「出海」觀察：多款獲批生物類似藥寄望海外收入超越國內","url":"https://stock-news.laohu8.com/highlight/detail?id=2667660668","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667660668?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 01:03","pubTimestamp":1789405401,"startTime":"0","endTime":"0","summary":"2026年上半年，中国创新药延续高增长态势。国家药监局数据显示，2026年1~6月，中国创新药对外授权交易共81笔，总额约1100亿美元，已达2025年全年总额的八成，创历史新高。《每日经济新闻》记者（以下简称每经记者）注意到，从上市公司半年报来看，首付款作为部分企业BD（商务拓展）收入的一部分，让利润表短暂“翻红”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609153873800338.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609153873800338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","MEDX","IE00B5TLWC47.USD","LU2272731865.HKD","06978","LU1992135472.HKD","IBBQ","BK1161","BK4588","LU2272731782.SGD","PPH","LU2322448957.HKD","159992","LU2272731600.USD","LU2473716301.USD","LU2322448791.USD","LU1992135399.USD","XPH","IBB","LNGR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667366424","title":"創新藥板塊迎來近一個月最大漲幅，這些國產創新藥在「2026世界肺癌大會」讀出亮眼數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2667366424","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667366424?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 22:40","pubTimestamp":1789396854,"startTime":"0","endTime":"0","summary":"9月14日，低迷了近一个月的创新药板块迎来上涨。截至收盘，创新药（BK1106）、创新药（HK1105）分别上涨2.38%、3.42%。个股方面，诺诚健华、映恩生物、乐普生物、康方生物领跑港股。消息面上，9月12日—15日召开的“2026世界肺癌大会（WCLC）”成为板块最强催化，多家国产药企密集交出重磅临床数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873752330.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873752330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159992","BK1161","LNGR","06978","MEDX","IBBQ","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667466104","title":"CRO板塊強勢走高！多家CRO上市公司解密業務近況","url":"https://stock-news.laohu8.com/highlight/detail?id=2667466104","media":"微博财经-财道工作室","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667466104?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 21:08","pubTimestamp":1789391280,"startTime":"0","endTime":"0","summary":"在互动平台与机构调研中，多家具备CRO业务的上市公司近期密集回应市场关切，披露了订单、产能及全球化布局的最新进展。2026 年上半年，公司实现 CRO 销售收入 4,513.95 万元， 较上年同期增长 10.91%。截至 2026 年上半年末，客户群体不断扩大，累计服务超过 16,900 家研发实验室客户。CRO 业务毛利率基本保持相对稳定水平，具体受服务类型、项目内容影响有所波动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2026-09-14/doc-inirveaq9305051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MEDX","BK4080","ADC","BK1161","NETL","06978","LNGR","IBBQ","BK1574","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667886669","title":"我國創新藥出海再提速 今年對外授權突破1200億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667886669","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667886669?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 20:58","pubTimestamp":1789390730,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LNGR","IBBQ","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667666143","title":"智通港股解盤 | 美國放緩AI另有玄機 WCLC大會再度催化創新藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2667666143","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667666143?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 20:45","pubTimestamp":1789389921,"startTime":"0","endTime":"0","summary":"科技股的走弱，和 Anthropic、OpenAI 与 SpaceX 罕见联手集体呼吁放缓AI 开发步伐有关。业绩方面，多光谱 AI 大模型服务收入冲到 3.20 亿元，同比暴涨 382.5%，收入占比直接从 29.8% 飙升至 78%。机构认为，2026 年 WCLC 大会的主角仍是 IO2.0 与 ADC，肺癌领域尤其是 1L 非小细胞肺癌的标准治疗范式正处于迭代前夜，国产双抗与 ADC 的进度全球领先。授权品种的里程碑付款与商业化分成，正在成为创新药企业价值兑现的第二曲线。这是公司首款双抗 ADC 获批临床，也是公司第三款 ADC 创新药进入临床。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495830.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CHAT","06978","LU0348735423.USD","01193","BK1566","IE00B543WZ88.USD","06160","LU0307460666.USD","02688","LU0593848301.USD","IE00BPRC5H50.USD","IE00BZ08YS42.EUR","VXUS","IE00BMCWC346.EUR","BK1521","AGIX","VTHR","LU0431992006.USD","LNGR","LU0651946864.USD","LU1051768304.USD","LU1515016050.SGD","MEDX","LU0877626530.USD","IE00BZ08YR35.GBP","159992","QTOC","BK1500","IE00BGHQDM52.EUR","ARTY","AIPO","KCAI","LU1969619763.USD","09969","BK1161","LU0640798160.USD","LU0821914370.USD","LU1808992512.USD","00135","IE0008369823.USD","IE00BZ08YT58.USD","BK4588","LU0287142896.SGD","LU1224709979.USD","KURE","IBBQ","06690","BK1574","IE00B29SXG58.USD","IE0034224299.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668966","title":"縮量震盪下，創新藥逆市爆發，中證銀行指數上探年內新高！光模塊回調，高「光」ETF獲資金逢低關注","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668966","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668966?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:10","pubTimestamp":1789384200,"startTime":"0","endTime":"0","summary":"AI硬件赛道普遍回调，受硅谷“降速”言论影响，光模块龙头承压明显，高“光”创业板人工智能ETF华宝标的指数收跌2%，资金逢低关注布局机会。分红方面，国有六大行2026年度中期现金分红总额拟超2000亿元，同时为进一步增强投资者的获得感，均将中期拟分红比例由30%提高至31%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-14/doc-iniruxuu7290017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AAOZ","LYTE","BK1574","AAOX","BK1161","06978","AAOG","399986","BK4550","BK4585","FDN","159992","IBBQ","BK4588","159253","LNGR","MEDX","LUMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667668638","title":"博安生物：BA1203獲准開展臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2667668638","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667668638?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:04","pubTimestamp":1789383840,"startTime":"0","endTime":"0","summary":"南财智讯9月14日电，博安生物（06955.HK）发布自愿公告，公司自主研发的在研PD-1/IL-2抗体细胞因子前药BA1203的新药临床试验申请（IND）已获得中国国家药品监督管理局药品审评中心（CDE）批准，拟开发用于多种实体瘤的治疗。BA1203为全球唯一的IL-2α受体高活性、遮蔽型且PD-1阻断型PD-1/IL-2分子。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873558977.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873558977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MDTX","06955","IBBQ","PSYK","BK1161","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667685646","title":"ETF日報：短期看在A股整體市場動能偏弱、熱點輪動加快的環境下，前期調整的創新藥、CXO板塊擁有一定性價比","url":"https://stock-news.laohu8.com/highlight/detail?id=2667685646","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667685646?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:02","pubTimestamp":1789383720,"startTime":"0","endTime":"0","summary":"形成赛道级利好共振，重塑市场对创新药研发进度与商业化价值的预期，修复创新药β行情，抬升CXO产业链订单与研发景气度预期。前期创新药、CXO板块经历持续回调，整体估值与市场情绪充分降温，板块点位回落至6-8月宽幅震荡箱体下沿位置，具备一定的技术性反弹空间。展望后市，短期看，在A股整体市场动能偏弱、热点轮动加快、反弹逐步收敛的环境下，前期调整的创新药、CXO板块拥有一定性价比。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-14/doc-iniruxuw4057482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["83130","02846","159982","BK1574","LNGR","03130","BK1147","BK4588","06978","BK4550","83188","MEDX","02827","FDN","399300","159992","BK4585","IBBQ","WX","03188","CXO","07233","82846","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667657414","title":"康哲藥業(00867)：創新藥高選擇性TYK2抑制劑CMS-D001 獲得系統性紅斑狼瘡適應症藥物臨床試驗批准通知書","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657414","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657414?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 18:23","pubTimestamp":1789381419,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 公布，于2026年9月11日，创新药CMS-D001片获得中国国家药品监督管理局签发的药物临床试验批准通知书，于2026年9月14日收到药物临床试验批准通知书。NMPA同意集团开展临床试验以评价CMS-D001治疗系统性红斑狼疮适应症的有效性和安全性。CMS-D001作为高选择性TYK2抑制剂，相较于泛JAK抑制剂，CMS-D001对其他JAK家族激酶的影响较小，可在长期疾病控制中维持疗效并降低相关安全风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495742.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","BK1161","BMED","LNGR","159992","IBBQ","IE00BGHQDM52.EUR","IE00BVYPNQ40.USD","00867","IE00BVYPNP33.GBP","SG9999015945.SGD","MEDX","06978","PSYK","SG9999015978.USD","SG9999004311.SGD","LU2488822045.USD","SG9999004220.SGD","SG9999015952.SGD","BK1593","SG9999015986.USD","IE00BYV24P56.USD","IBBJ","BK1191","IE00BMCWC346.EUR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667657480","title":"康哲藥業：9月14日CMS-D001獲SLE臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657480","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657480?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 18:23","pubTimestamp":1789381383,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","MDTX","SLE","BMED","IBBQ","IBBJ","BK4077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667657738","title":"恒瑞創新藥凝血因子XI單抗SHR-2004注射液用於擇期膝關節置換手術後成年患者靜脈血栓預防的上市申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657738","media":"恒瑞医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657738?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:59","pubTimestamp":1789379940,"startTime":"0","endTime":"0","summary":"近日，恒瑞医药子公司北京盛迪医药有限公司收到国家药监局下发的《受理通知书》，公司1类创新药、凝血因子XI单克隆抗体SHR-2004注射液的药品上市许可申请获受理，拟定适应症为：用于择期膝关节置换手术的成年患者，以预防静脉血栓形成。该研究旨在评价行择期TKA的患者使用SHR-2004注射液预防静脉血栓栓塞症的有效性和安全性。此外，SHR-2004用于卵巢癌术后VTE预防的Ⅱ期试验已完成。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-09-14/doc-iniruxuy4531842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","LNGR","159992","IPOS","06978","MEDX","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667654298","title":"白雲山：超10個創新藥管線引進項目已完成立項","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654298","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667654298?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 17:36","pubTimestamp":1789378605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MEDX","LNGR","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667582651","title":"ETF日報(09.14)丨WCLC臨床數據密集兑現，創新藥板塊震盪回升 算力需求預期遭重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2667582651","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667582651?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:44","pubTimestamp":1789375451,"startTime":"0","endTime":"0","summary":"WCLC临床数据密集兑现，创新药板块震荡回升；AI巨头集体\"喊停\"，算力需求预期遭重估，通信板块多数走低。行业表现WCLC临床数据密集兑现，国内外投行相继看好中国CRO/CDMO复苏明确，创新药板块震荡回升。消息面上，9月12日至15日，2026年世界肺癌大会在韩国首尔举行，多项国产创新药临床数据集中亮相，中国新药入选口头报告19项、小型口头报告45项，双双刷新历史纪录，肺癌领域ADC与双抗数据成为焦点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495613.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","LNGR","MEDX","FDN","06978","BK4585","BK4550","EPAI","AIVC","BAI","159992","BK1161","AIQD","AIQU","IBBQ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667599986","title":"阿斯利康(AZN.US)乳腺癌藥物Etcamah三期臨床試驗受挫 或致數十億美元銷售額蒙陰","url":"https://stock-news.laohu8.com/highlight/detail?id=2667599986","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667599986?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:27","pubTimestamp":1789374476,"startTime":"0","endTime":"0","summary":"Bloomberg Intelligence分析师John Murphy表示，阿斯利康此次乳腺癌药物试验受挫可能使2035年的销售额减少26亿至38亿美元。ESR1突变是ER阳性乳腺癌内分泌治疗耐药的重要机制。CAMBRIA-1比较Etcamah延长辅助治疗5年 vs 标准内分泌治疗，中高复发风险。如果CAMBRIA阳性，Etcamah的市场空间将远大于晚期ESR1突变人群——这也是阿斯利康对Etcamah 50亿美元峰值销售额预期的核心支撑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBJ","PSYK","BMED","IBBQ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667599576","title":"阿斯利康(AZN.US)乳腺癌藥物Etcamah三期臨床試驗受挫 或致數十億美元銷售額蒙陰","url":"https://stock-news.laohu8.com/highlight/detail?id=2667599576","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667599576?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:27","pubTimestamp":1789374476,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","MDTX","IBBJ","BMED","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667554366","title":"ETF異動 | 華夏恒生生科(03069)升逾4% WCLC臨床數據催化密集 機構看好創新藥投資機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2667554366","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667554366?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:17","pubTimestamp":1789370250,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华夏恒生生科涨超4%。截至发稿，涨4.01%，报15.58港元，成交额6924.78万港元。本次WCLC会议上，中国新药表现亮眼，入选口头报告研究19项，小型口头报告研究45项，刷新记录。国金证券称，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","LNGR","159992","FDN","03069","06978","BK4585","MEDX","BK1574","BK4550","BK4588","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":3,"totalSize":214,"code":"91000000","status":"200"}]}}